Aspira Women's Health Inc.
AWHL- Exchange
- OTC
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000926617
No open-market purchases or sales by Aspira Women's Health Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Aspira Women's Health Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 22 | 24 | +2 |
| Shares | 530.0K | 657.8K | +127.9K (+24.1%) |
| Value | $1.75M | $3.53M | +$1.77M (+101.0%) |
New holders (4)
Institutions that held Aspira Women's Health Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Perkins Capital Management Inc | 50,000 | $268.0K | 0.27% |
| Northeast Financial Consultants Inc | 23,436 | $125.6K | 0.01% |
| Susquehanna International Group, LLP | 12,156 | $65.2K | 0.00% |
| Northern Trust Corp | 11,002 | $59.0K | 0.00% |
Sold out (2)
Institutions that held Aspira Women's Health Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Royal Bank of Canada | 1,546 | $5.00K |
| Steward Partners Investment Advisory, LLC | 313 | $1.04K |